Roche is facing competition for several of its cancer drugs from biosimilars, as reported euronews Tuesday.
Experts noted that the uptake of biosimilars of Roche's Herceptin has been far more rapid than that of Johnson & Johnson and Merck & Co.'s Remicade.
Ho-Ung Kim, head of strategy and operations at Celltrion, estimated that the rapid uptake of biosimilars of Herceptin will save European healthcare systems 1.2 billion euros over the next five years.
Roche is expecting four of five competitors to launch biosimilars of Herceptin this year, compared to only two for Rituxan.
Celltrion could launch its Herceptin biosimilar by April, while Samsung Bioepis has already received European clearance of its competing therapy.
Conversely, analysts believe the uptake of biosimilar versions of Rituxan, Herceptin and Avastin will be much slower in the US.
To read more NewsPoints articles, click here.